Emyria Ltd has released a press release.
Emyria receives ethics approval for EMD-RX5 Phase 3 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Emyria
- Preclinical studies initiated for MDMA-inspired analogues
- Appendix 4C - Quarterly
- Emyria expands drug candidate library inspired by MDMA
- Emyria expands MDMA analogue program with UWA
- EMD-RX5 demonstrates excellent safety and bioavailability
Later from Emyria
- Positive results received for Emyrias MDMA-inspired program
- Appendix 4E and Annual Report
- Emyria commences US preclinical program for MDMA library
- Emyria expands clinical sites for EMD-RX5 Phase 3 trial
- Emyria and UWA expand unique MDMA-inspired analogue library
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria